<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066599</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316329</org_study_id>
    <secondary_id>NCI-03-C-0218</secondary_id>
    <nct_id>NCT00066599</nct_id>
    <nct_alias>NCT00062920</nct_alias>
  </id_info>
  <brief_title>Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy</brief_title>
  <official_title>An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - &lt;12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following
      chemotherapy.

      PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic
      fungal infections in children who have neutropenia after receiving chemotherapy for leukemia,
      lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the pharmacokinetics of voriconazole administered IV and orally for the
           prevention of systemic fungal infection in pediatric patients with neutropenia after
           chemotherapy.

        -  Determine the safety and tolerability of this drug in these patients.

      OUTLINE: This is a pilot, open-label, multicenter study. Patients are stratified according to
      age (2 to 5 vs 6 to 11).

      Within 48 hours after completion of chemotherapy, patients begin prophylactic therapy:

        -  Cohort 1 (the first 18 patients, 9 per stratum): Patients receive voriconazole IV over
           80-160 minutes twice daily on days 1-8 and oral voriconazole* twice daily beginning on
           day 9.

      Depending on the results of the interim pharmacokinetic analysis, the last 18 patients
      entered on the study receive 1 of the following regimens:

        -  Cohort 2A:Patients receive voriconazole as in cohort 1 at a higher dose.

        -  Cohort 2B: Patients receive voriconazole IV over 80-160 minutes twice daily on days 1-4
           and oral voriconazole* twice daily beginning on day 5.

      NOTE: *Patients who are unable to tolerate oral medication may continue receiving IV
      medication until day 20.

      In all cohorts, treatment continues until blood counts recover or day 30 in the absence of
      unacceptable toxicity or progression of infection.

      Patients are followed at 30 days and at 12 months.

      PROJECTED ACCRUAL: A total of 49 patients (approximately 24 per stratum) were accrued for
      this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Neuroblastoma</condition>
  <condition>Neutropenia</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voriconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Expected to develop neutropenia (absolute neutrophil count less than 500/mm^3) lasting
             for more than 10 days after chemotherapy for 1 of the following conditions:

               -  Leukemia

               -  Lymphoma

               -  Aplastic anemia

               -  Preparation for a bone marrow or stem cell transplantation

          -  Requiring treatment for the prevention of systemic fungal infection

        PATIENT CHARACTERISTICS:

        Age

          -  2 to 11

        Performance status

          -  Not specified

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  AST and ALT no greater than 5 times upper limit of normal (ULN)

          -  Bilirubin no greater than 5 times ULN

        Renal

          -  Creatinine clearance at least 30 mL/min

        Cardiovascular

          -  No cardiac arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No severe hypokalemia (potassium less than 3.2 mmol/L)

          -  No prior hypersensitivity to or severe intolerance of azole antifungal agents

          -  No other concurrent condition that would preclude study therapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  At least 24 hours since prior use of any of the following:

               -  Terfenadine

               -  Pimozide

               -  Quinidine

               -  Astemizole

               -  Cisapride

               -  Omeprazole

          -  More than 14 days since prior use of any of the following:

               -  Rifampin

               -  Rifabutin

               -  Carbamazepine

               -  Phenytoin

               -  Nevirapine

               -  Long-acting barbiturates

          -  No prior sirolimus

          -  No prior enrollment on this study

          -  No concurrent use of any of the following:

               -  Terfenadine

               -  Pimozide

               -  Quinidine

               -  Astemizole

               -  Cisapride

               -  Omeprazole

          -  No other concurrent investigational drugs except any of the following:

               -  Drugs used as treatment for cancer

               -  Antiretroviral agents

               -  Drugs used for the treatment of any AIDS-defining opportunistic infections

          -  No concurrent enrollment in investigational anticancer drug trials that exclude the
             use of other investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J. Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Health Center, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>neutropenia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

